Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
180 studies found for:    panitumumab
Show Display Options
Rank Status Study
1 Terminated
Has Results
Panitumumab and Irinotecan for Malignant Gliomas
Condition: Malignant Glioma of Brain
Interventions: Drug: Irinotecan;   Drug: Panitumumab
2 Active, not recruiting Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: Panitumumab
3 Active, not recruiting Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Panitumumab;   Drug: Carboplatin;   Drug: Gemcitabine
4 Recruiting Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Panitumumab;   Drug: Cabozantinib
5 Completed
Has Results
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Condition: Colorectal Cancer
Interventions: Drug: Oxaliplatin Based Chemotherapy;   Drug: Panitumumab;   Drug: Irinotecan Based Chemotherapy;   Drug: Bevacizumab
6 Terminated
Has Results
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Panitumumab;   Procedure: Surgery;   Procedure: Radiation Therapy
7 Completed Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-type KRAS mCRC
Conditions: Colon Cancer;   Colorectal Cancer;   Gastrointestinal Cancer;   Metastatic Colorectal Cancer;   Rectal Cancer
Interventions: Drug: Panitumumab + AMG 102;   Drug: Panitumumab + AMG 479;   Drug: AMG 479;   Drug: AMG 102;   Drug: Panitumumab
8 Active, not recruiting Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Panitumumab
9 Completed
Has Results
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Conditions: Colorectal Cancer;   Metastatic Cancer
Intervention: Biological: Panitumumab
10 Completed
Has Results
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Biological: Panitumumab;   Drug: 5-Fluorouracil;   Drug: Leucovorin
11 Terminated
Has Results
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
Conditions: Lung Cancer;   Pancreatic Cancer;   Esophageal Cancer
Interventions: Drug: AMG 706;   Biological: Panitumumab;   Drug: Gemcitabine;   Drug: Cisplatin
12 Completed Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Conditions: Rectal Cancer;   Colon Cancer
Interventions: Drug: FOLFOX-4;   Drug: AMG 706;   Biological: Panitumumab (Part 1a only);   Drug: FOLFIRI
13 Active, not recruiting Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: Panitumumab;   Drug: Cisplatin;   Radiation: Radiation Therapy
14 Recruiting Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Maintenance Chemotherapy;   Drug: Panitumumab (Within maintenance phase);   Drug: mFOLFOX6 (Within re-induction phase);   Drug: Panitumumab (Within re-induction phase)
15 Recruiting Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: panitumumab;   Drug: Randomization to No Panitumumab
16 Unknown  PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)
Condition: Cholangiocarcinomas
Interventions: Drug: Cisplatin, Gemcitabine, Panitumumab;   Drug: Cisplatin, Gemcitabine
17 Recruiting Panitumumab Pediatric Study
Condition: Solid Tumors
Intervention: Drug: Panitumumab Treatment
18 Completed
Has Results
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of Head and Neck
Interventions: Drug: Panitumumab;   Drug: Cisplatin;   Drug: 5FU
19 Active, not recruiting
Has Results
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Conditions: Colon Cancer;   Colorectal Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab;   Drug: Bevacizumab;   Drug: mFOLFOX6
20 Completed Chemoradiation and Panitumumab for Esophageal Cancer
Conditions: Squamous Cell Carcinoma;   Adenocarcinoma;   Esophageal Cancer;   Gastro-esophageal Junction Cancer
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: panitumumab;   Radiation: radiotherapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years